outbrain
Close  

FDA OKs drug to block infection after marrow transplant

/ 08:15 AM November 09, 2017

In this February 28, 2013 photo, a Merck scientist conducts research in West Point, Pa. On Wednesday, November 8, 2017, the Food and Drug Administration approved sales of Merck and Co.’s Prevymix, the first drug to prevent life-threatening infections in adults after a bone marrow transplant. (AP FILE PHOTO)

TRENTON, N.J. — United States regulators have approved the first drug to prevent life-threatening infections in adults after a bone marrow transplant.

The Food and Drug Administration (FDA) approved on Wednesday the sales of Merck and Co.’s Prevymix (PREH’-vih-miss) to prevent infections with cytomegalovirus (sy-toe-MEG’-a-low-vy-rus), a common virus. It does not sicken most people, but strikes at least half of transplant patients, who are particularly vulnerable to infection. The virus can damage the eyes, lungs and other organs, trigger pneumonia, and even cause death.

ADVERTISEMENT

Merck, which is based in Kenilworth, New Jersey, said the drug would cost $195 to $270 per day for 100 days.

Each year, about 8,500 Americans receive transplants of blood-forming cells from bone marrow to treat blood cancers or other blood disorders. Currently, they get antiviral therapy if they develop an infection, rather than a preventive treatment.           /kga

FEATURED STORIES

TOPICS: cytomegalovirus, drug, FDA, Health, infection, marrow, Medicine, Merck and Co., Prevymix, Science, Transplant, Virus
Read Next
EDITORS' PICK
MOST READ
Don't miss out on the latest news and information.
View comments

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2020 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.